title: CSF-tau and CSF-Abeta(1-42) in posterior cortical atrophy.
abstract: OBJECTIVE
  Our purpose was to measure Abeta(1-42), T-tau and P-tau(181) in the cerebrospinal fluid (CSF) of patients with posterior cortical atrophy (PCA), a presenile dementia likely to represent a variant of Alzheimer's disease (AD).
  
  
  METHODS
  CSF samples from 34 subjects including 9 patients with PCA, 11 age-matched patients with AD and 14 age-matched cognitively healthy controls were analyzed using commercially available ELISA kits.
  
  
  RESULTS
  The Abeta(1-42), T-tau and P-tau(181) levels in PCA patients differed significantly (p < 0.02) from those in healthy controls but were indistinguishable from subjects with a clinical diagnosis of AD.
  
  
  CONCLUSIONS
  High T-tau and P-tau(181) and low Abeta(1-42) levels in PCA - typically observed in AD - indicate that the underlying pathology of PCA is usually AD. If these findings are replicated in PCA patients with autopsy-confirmed AD neuropathology, PCA patients may be eligible for disease-modifying AD treatments.
authors.affiliation: Memory Clinic-Neuropsychology Center, Department of Geriatrics, University Hospital, Basel, Switzerland. th.baumann@unibas.ch
authors.forename: Thomas P
authors.initials: TP
authors.lastname: Baumann
authors.forename: Hüseyin
authors.initials: H
authors.lastname: Duyar
authors.forename: Marc
authors.initials: M
authors.lastname: Sollberger
authors.forename: Jens
authors.initials: J
authors.lastname: Kuhle
authors.forename: Axel
authors.initials: A
authors.lastname: Regeniter
authors.forename: Baltazar
authors.initials: B
authors.lastname: Gomez-Mancilla
authors.forename: Klaus
authors.initials: K
authors.lastname: Schmidtke
authors.forename: Andreas U
authors.initials: AU
authors.lastname: Monsch
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000145:classification / Q000473:pathology; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D001284:Atrophy / Q000134:cerebrospinal fluid; D015415:Biomarkers / Q000134:cerebrospinal fluid; D001921:Brain / Q000473:pathology*; D016022:Case-Control Studies; D003072:Cognition Disorders / Q000134:cerebrospinal fluid* / Q000473:pathology; D003704:Dementia / Q000134:cerebrospinal fluid* / Q000145:classification / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D016555:Matched-Pair Analysis; D008875:Middle Aged; D010446:Peptide Fragments / Q000134:cerebrospinal fluid*; D012016:Reference Values; D016875:tau Proteins / Q000134:cerebrospinal fluid*
chemical_list: D016229:Amyloid beta-Peptides; D015415:Biomarkers; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D016875:tau Proteins